Phase 2 N=35 Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Metabolic Syndrome X · Overweight · Hypertension
Primary: Insulin Sensitivity — .56; 0.55; 0.66; 0.70 % suppression inf rate 56 pmol/m2/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=121 A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Metastatic Non-small Cell Lung Cancer · Locally Advanced Urothelial Cancer · Metastatic Urothelial Cancer
Primary: Overall Response Rate (ORR) — 40.0; 34.8; 37.9; 23.5 percentage of participants
Phase 2 N=26 Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
HIV/AIDS · Antiviral Toxicity · Antiviral Drug Adverse Reaction
Primary: Change in Mitochondrial Function [Cellular Oxygen Consumption (COC)] Over 12 Months After Switch of Antiretrovirals. — 50; 70 pmoles O2/min — p=<0.001
Phase 2 N=208 MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
Advanced Malignant Solid Neoplasm
Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants
Phase 2 N=200 Oxytocin, Alcohol Craving, and Intimate Partner Aggression
Alcohol Use
Primary: Change in Alcohol Craving — 0.90; 1.21 score on a scale
Phase 2 N=21 Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
Chronic Graft-Versus-Host Disease · Immune System Diseases
Primary: Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide — 15 Participants
Phase 2 N=79 A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
Parkinson Disease
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 45; 20; 5; 0 participants
Phase 2 N=274 An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Gastric Cancer · Cancer of the Stomach · Esophagogastric Junction
Primary: BICR-Assessed Objective Response Rate (ORR) in Randomized LAG-3 Positive (>=1 %) Participants — 48.5; 61.2 Percentage of Participants
Phase 2 N=22 Weekly Isotretinoin Therapy Study
Acne Vulgaris
Primary: Number of Participants That Showed Improvement in Their Visible Acne (Efficacy of Once Weekly Isotretinoin) — 18 Participants
Phase 2 N=161 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Follicular Lymphoma (FL) · CLL · Small Lymphocytic Lymphoma (SLL)
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 160 Number of participants
Phase 2 N=20 Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Metastatic Castrate-resistant Prostate Cancer · mCRPC
Primary: Time to Progression — 11.2 weeks
Phase 2 N=563 An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Early Stage HER2+ Breast Cancer
Primary: Percentage of Patients With Grade 3 or Higher Diarrhea, According to NCI CTCAE v4.0. — 30.7; 28.1; 20.6; 32.7 Percentage of participants
Phase 2 N=96 Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Objective Tumour Response Evaluated According to the Response Evaluation Criteria in Solid Tumours (RECIST 1.0) by Central Review of the Tumour Images — 2; 0; 0; 0…
Phase 2 N=11 Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 1; 1; 7; 1 participants
Phase 2 N=45 Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children
New Daily Persistent Headache (NDPH)
Primary: Pain Intensity — 5.82; 4.92 score on a scale